论文部分内容阅读
目的比较低剂量国产长春瑞滨(盖诺)连续静脉滴注与传统的快速静脉滴注疗法联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法将71例晚期NSCLC患者随机分为连续静滴组、快速静滴组两组。连续静滴组35例,盖诺首次剂量10mg加入NS40ml中静推,然后将盖诺10mg加入NS250ml中静脉滴注,连用5d,盖诺总剂量60mg,顺铂40mg静脉滴注,连用3d,每3周重复,2周期以上评价疗效;快速静滴组36例,于第1天和第8天将盖诺40mg加入NS100ml中静脉滴注,盖诺总剂量80mg,顺铂用法用量同前,每3周重复,2周期以上评价疗效。结果两组的有效率分别为42.86%和47.22%,中位生存期分别为13.2月和14.1月,中位缓解期分别为5.6月和5.9月。两组最常见的血液学毒性均为中性粒细胞减少,Ⅲ～Ⅳ骨髓抑制为20.00%、52.78%,差异有统计学意义。结论两组的有效率分别为42.86%和47.22%,中位生存期分别为13.2月和14.1月,中位缓解期分别为5.6月和5.9月。两组最常见的血液学毒性均为中性粒细胞减少,Ⅲ～Ⅳ骨髓抑制为20.00%、52.78%,差异有统计学意义。
Objective To compare the curative effect and toxicity of continuous intravenous drip of vinorelbine (Gynoside) and traditional fast intravenous drip combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Seventy-one patients with advanced NSCLC were randomly divided into continuous intravenous infusion group and rapid intravenous infusion group. Continuous intravenous drip group of 35 cases, the first dose of 10 g Gelano injection NS40ml in the static push, and then add 10 g of Gentamycin NS250ml intravenous drip, even 5d, total dose of Gelano 60mg, cisplatin 40mg intravenous infusion, once every 3d, 3 weeks repeated, more than 2 cycles evaluation of efficacy; rapid intravenous infusion of 36 cases, on the first day and day 8 will Gentano 40mg added NS100ml intravenous infusion, the total dose of 80g Generol, cisplatin dosage as before, every 3 weeks repeated, 2 cycles or more evaluation of efficacy. Results The effective rates of the two groups were 42.86% and 47.22% respectively, and the median survival time was 13.2 months and 14.1 months respectively. The median remission rates were 5.6 months and 5.9 months respectively. The two groups of the most common hematological toxicity were neutropenia, Ⅲ ~ Ⅳ myelosuppression was 20.00%, 52.78%, the difference was statistically significant. Conclusions The effective rates of the two groups were 42.86% and 47.22% respectively, and the median survival time was 13.2 months and 14.1 months respectively. The median remission rates were 5.6 months and 5.9 months respectively. The two groups of the most common hematological toxicity were neutropenia, Ⅲ ~ Ⅳ myelosuppression was 20.00%, 52.78%, the difference was statistically significant.